Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 114. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Use of artificial intelligence to enhance detection of nodal metastases793
SABR for operable stage I non-small-cell lung cancer: comparison to surgery722
Patients with cancer in Louisiana denied fertility preservation cover549
Innovation in gynaecological cancer: highlighting global disparities492
Combination immunotherapy in chemotherapy in gastric cancer488
US FDA proposes stronger laboratory test oversight470
Correction to Lancet Oncol 2022; 23: 1124–26451
Correction to Lancet Oncol 2021; 22: 309–20434
COVID-19 pandemic causes cervical cancer screening crisis420
Medical treatment for active breast cancer brain metastases390
Enhancing equity and long-term impact assessments in radiotherapy environmental studies380
IVLBCL mimicking VEXAS syndrome374
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy372
The GLOW trial in chronic lymphocytic leukaemia350
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer344
Dual therapy in metastatic castration-resistant prostate cancer322
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply317
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer306
Italy to pass law on the right to be forgotten for cancer survivors304
Palliative radiotherapy for hepatic cancer pain301
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges294
Study bolsters concerns about US FDA accelerated drug approvals291
Olanzapine for chemotherapy-induced nausea and vomiting control288
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer284
US Surgeon General calls for cancer warning labels on alcohol283
CAR T cells for the long run in aggressive B-cell lymphoma280
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study278
Correction to Lancet Oncol 2021; 22: 1081–92276
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi275
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC271
Antibody–drug conjugates in acute myeloid leukaemia: more research needed265
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, 263
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia262
A new generation of comprehensive precision oncology trials258
The silent malignant mesothelioma epidemic: a call to action256
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis256
Precision medicine for children with cancer252
The future of precise cancer chronotherapeutics243
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study239
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study235
Survivorship after neoadjuvant chemotherapy232
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial227
Impact of COVID-19 on cancer care in India: a cohort study225
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries224
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t224
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial216
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation209
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 209
Determining the optimal use of approved drugs in oncology209
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm209
Concern for cancer drugs in USA–EU tariff war207
Navigating the complexity: reflections on the development of perioperative cancer treatments204
Health insurance system in Japan faces risk of politicisation202
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial202
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult194
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery193
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial190
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies187
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial187
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under181
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 181
Focus where it matters: turning insights into advocacy179
Decentralised, point-of-care CAR-T for multiple myeloma178
A biobank perspective on use of tissue samples donated by trial participants177
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study177
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer177
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit175
Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis171
Common Sense Oncology: including everyone170
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?166
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply164
Essential anticancer medicines for children: defining what matters most for Europe163
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply163
Importance of clinical research for the UK's 10-year cancer plan160
Lung cancer rates highest among British Bangladeshi men160
Greater price transparency needed for thyroid cancer treatment among US cancer centres160
Balancing clinical benefit and social value: challenges in HTA assessments159
Adjuvant therapy in stage IIIA melanoma - Authors' reply155
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo153
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:151
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update150
Radiotherapy with genomic-adjusted radiation dose149
Radiotherapy with genomic-adjusted radiation dose148
Mantle cell lymphoma: is it time for risk-adapted treatment?148
Lebanon faces critical shortage of drugs147
India rolls out HPV vaccination146
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti144
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis143
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer142
Cancer on the agenda during IAEA Director General's visit to Chile141
Challenges and prospects for cancer treatment in prison settings140
Daratumumab maintenance in patients with myeloma140
Correction to Lancet Oncol 2020; 21: 699–709137
Correction to Lancet Oncol 2023; 24: e242137
2022 ASTRO annual meeting136
Clearing the radiotherapy backlog: innovation to pave the way136
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus133
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial133
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK132
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup130
A growing vulvar mass in a post-menopausal woman130
Radiotherapy and conflict: from disruption to expansion and hope129
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis128
Shortages of essential medications for children with cancer in Colombia127
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire127
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA126
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study125
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra123
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations122
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial122
Alcohol and the global burden of cancer: what are we missing?118
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study117
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer116
Syrian cancer patients regain treatment access in Türkiye114
0.088625907897949